
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics Inc. is experiencing a positive outlook driven by an increase in its modeled peak market penetration for cadisegliatin (TTP399) to 25%, reflecting enhanced confidence in its risk-adjusted DCF valuation. The management has reported promising progress in the CATT1 study, which bolsters faith in the drug's ongoing development and its potential impact in providing an innovative oral therapy for type 1 diabetes patients. Furthermore, the strategic position of cadisegliatin as the only oral adjunctive therapy in late-stage development for T1D highlights its competitive advantage in a market burdened by existing injection methods, paving the way for significant commercial potential.
Bears say
vTv Therapeutics's stock faces a negative outlook primarily due to challenges with its lead candidate, cadisegliatin (TTP399), which remains in late-stage development and is subject to clinical risks such as slower patient enrollment and potential safety and efficacy concerns that may not align with earlier study results. Historical data indicates significant setbacks with first-generation glucokinase activators, including issues related to hypoglycemia and diminishing glycemic benefits over time, which could foreshadow similar problems for TTP399. Additionally, the context of nearly 80% of adults with type 1 diabetes failing to meet the American Diabetes Association's A1C threshold highlights the difficulties in achieving effective glucose control, thereby raising doubts about the commercial viability of vTv Therapeutics's pipeline.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares